Automate Your Wheel Strategy on DXCM
With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DXCM
- Rev/Share 12.0559
- Book/Share 7.1011
- PB 10.3167
- Debt/Equity 0.5061
- CurrentRatio 1.8825
- ROIC 0.1661
- MktCap 28572591647.0
- FreeCF/Share 2.7856
- PFCF 26.5249
- PE 33.875
- Debt/Assets 0.2192
- DivYield 0
- ROE 0.3244
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | DXCM | Barclays | Equal Weight | Underweight | -- | $71 | Jan. 12, 2026 |
| Upgrade | DXCM | Morgan Stanley | Equal Weight | Overweight | -- | $75 | Dec. 2, 2025 |
| Initiation | DXCM | Evercore ISI | -- | In-line | -- | $68 | Nov. 25, 2025 |
| Resumed | DXCM | Stifel | -- | Buy | -- | $85 | Oct. 21, 2025 |
| Downgrade | DXCM | Oppenheimer | Outperform | Perform | -- | -- | Sept. 8, 2025 |
| Initiation | DXCM | Argus | -- | Buy | -- | $100 | Aug. 21, 2025 |
| Initiation | DXCM | Truist | -- | Buy | -- | $102 | June 16, 2025 |
| Initiation | DXCM | Goldman | -- | Buy | -- | $104 | May 30, 2025 |
| Initiation | DXCM | Mizuho | -- | Outperform | -- | $85 | April 10, 2025 |
| Upgrade | DXCM | Redburn Atlantic | Neutral | Buy | $85 | $115 | Feb. 3, 2025 |
News
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
DXCM
Published: February 13, 2025 by: Reuters
Sentiment: Positive
Published: February 13, 2025 by: Reuters
Sentiment: Positive
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Read More
About DexCom, Inc. (DXCM)
- IPO Date 2005-04-14
- Website https://www.dexcom.com
- Industry Medical - Devices
- CEO Jacob Steven Leach
- Employees 10200
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.